黄晨蓉

姓名：黄晨蓉

技术职称：副教授

导师类别：硕士生导师

所在学科：临床药学

Email：huangchenrong@suda.edu.cn

简介：

黄晨蓉，副教授，副主任药师，硕士生导师，www.优德88.cpm 附属第一医院药学部主任助理，www.优德88.cpm 药物研究与转化交叉研究所办公室主任。专业主攻方向为治疗药物监测与个体化药物治疗和新药临床研究。

学习、工作经历：

1999.9-2003.6中国药科大学，国家药学理科基地班，本科/学士

2003.9-2006.6中国药科大学，药理学（药代动力学方向），研究生/硕士

2014.9-2018.6www.优德88.cpm ，药剂学，研究生/博士

2006.7-至今 www.优德88.cpm 附属第一医院药学部，主任助理

主要研究方向

1、治疗药物监测与个体化药物治疗

2、临床药理

科研项目（2013年至今）:

1、《基于PET脑纹状体D2/3受体显像技术评价抗帕金森病DR激动药罗匹尼罗的DR占有治疗窗及其机制研究》，国家自然科学基金青年科学基金项目，2016.1，编号81503159，17.9万。主持

2、《伊立替康对晚期结直肠癌患者合理用药研究》，江苏省药学会-奥赛康医院药学基金，2014.1，编号201312，1.5万。主持

3、《SLCO2B1基因多态性对口服阿替洛尔后个体差异的研究》，苏州市科技局苏州药学会—常州四药临床药学科研基金研究项目，2013.1，编号SYSD2012128，1万。主持

4、《基于转运体的药物相互作用对HD-MTX所致恶性血液病患者急性肾损的影响及其机制研究》，第五批姑苏人才科研项目，2019.1，编号GSWS2019036，30万。主持

获奖情况（近五年）：

1、2017,华夏医学科技奖二等奖,血管狭窄性疾病治疗干预的创新和临床应用

2、2015，江苏省医学新技术引进奖二等奖，非线性混合效应模型建模技术用于造血干细胞移植患者免疫抑制剂临床个体化药物治疗

3、2015，江苏医学科技奖三等奖，个体化治疗技术与服务平台的建立及其在临床合理用药中的应用评价

4、2018，苏州市第五批姑苏卫生人才计划卫生青年拔尖人才

5、2019，中华医学会临床药学分会优秀临床药师

学术任职:

中国药理学会治疗药物监测研究专业委员会副秘书长兼委员，中国药师协会治疗药物监测药师分会委员，江苏省药师协会研究型药师分会副主任委员，江苏省医学会临床药学分会委员兼科研秘书，江苏省药理学会临床药理专业委员会委员。

杂志编委：

《中国医院药学杂志》通讯编委，《医药导报》青年编委，《中国临床药理学与治疗学》青年编委。

代表文章：

[1] Liu X, Xue L, Zhang H, Xu Q, Zhang S, Ma S, Ding X, Liu L, Dong J, Qian L, Xia W, Jiang K,Huang C(通讯), Miao L. Phase I, First-in-Human, Single and Multiple Ascending Dose- and Food-Effect Studies to Assess the Safety, Tolerability and Pharmacokinetics of a Novel Anti-hepatitis B Virus Drug, Bentysrepinine (Y101), in Healthy Chinese Subjects. Clin Drug Investig. 2020 Jun;40(6):555-566

[2] Wang Y, Pan D,Huang C（并列一作）, Chen B, Li M, Zhou S, Wang L, Wu M, Wang X, Bian Y, Yan J, Liu J, Yang M, Miao L. Dose escalation PET imaging for safety and effective therapy dose optimization of a bispecific antibody. MAbs. 2020 Jan-Dec;12(1):1748322 Dose escalation PET imaging for safety and effective therapy dose optimization of a bispecific antibody. MAbs. 2020 Jan-Dec;12(1):1748322

[3] Bian Y, Zhang H, Ma S, Jiao Y, Yan P, Liu X, Ma S, Xiong Y, Gu Z, Yu Z,Huang C（通讯）, Miao L.Mass balance, pharmacokinetics and pharmacodynamics of intravenous HSK3486, a novel anaesthetic, administered to healthy subjects. Br J Clin Pharmacol. 2020 May 15. doi: 10.1111/bcp.14363

[4] Huang S, Xu Q, Liu L, Bian Y, Zhang S,Huang C（通讯）, Miao L.Effect of Green Tea and (-)-epigallocatechin Gallate on the Pharmacokinetics of Rosuvastatin. Curr Drug Metab. 2020;21(6):471-478

[5]Huang C, Xia F, Xue L, Liu L, Bian Y, Jin Z, Miao L. Coadministration of vindesine with high-dose methotrexate therapy increases acute kidney injury via BCRP, MRP2, and OAT1/OAT3. Cancer Chemother Pharmacol. 2020 Feb;85(2):433-441

[6] Xia F, Ma S, Bian Y, Yu D, Ma W, Miao M,Huang C(通讯), Miao L. A retrospective study of the correlation of in vitro chemosensitivity using ATP-TCA with patient clinical outcomes in acute myeloid leukemia. Cancer Chemother Pharmacol. 2020 Mar;85(3):509-515

[7]Huang C, Wang Z, Liu L, Liu X, Dong J, Xu Q, Zhang B, Miao L. Predicting the Dopamine D2 Receptor Occupancy of Ropinirole in Rats Using Positron Emission Tomography and Pharmacokinetic-Pharmacodynamic Modeling. Xenobiotica. 2019 49(2):143-151.

[8] Xiaoxue Liu,Chenrong Huang(并列一作), Ling Xue, Qingqing Xu, Wen Xia, Xing Li,Liyan Miao. Simultaneous determination of bentysrepinine (Y101) and its metabolites M8 and M9 in human plasma by UPLC-MS/MS and its application to a pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis. 2018 150:287-293.

[9] Linsheng Liu,Chenrong Huang(并列一作), Yicong Bian, Liyan Miao. GC-MS based metabolomics of CSF and blood serum: Metabolic phenotype for a rat model of cefoperazone-induced Disulfiram-Like Reaction. Biochemical and Biophysical Research Communications. 2017 490:1066-1073

[10]Chenrong Huang, Wei Wang, Liyan Miao. Determination of Cefaclor by UPLC-MS/MS for a Chinese pharmacokinetic study. Journal of Chromatographic Science, J Chromatogr Sci. 2014 Aug; 52(7):636-40.

[11]Chenrong Huang, Jie Gao, Liyan Miao. Simultaneous determination of flucloxacillin and ampicillin in human plasma by ultra performance liquid chromatography–tandem mass spectrometry and subsequent application to a clinical study in healthy Chinese volunteers. J Pharm Biomed Anal.2012 Feb 5; 59: 157-161

[12]Huang C, Yang J, Du Y, Miao L. Measurement of free concentrations of highly protein-bound warfarin in plasma by ultra performance liquid chromatography-tandem mass spectrometry and its correlation with the international normalized ratio. Clin Chim Acta. 2008 Jul; 393(2):85-9.

[13]Huang CR, Wang GJ, Wu XL, Li H, Xie HT, Lv H, Sun JG. Absorption enhancement study of astragaloside IV based on its transport mechanism in caco-2 cells. Eur J Drug Metab Pharmacokinet. 2006 Jan-Mar; 31(1):5-10.

[14]Huang C, Wang G, Li H, Xie H, Sun J, Lv H, Lv T. Sensitive and selective liquid chromatography-electrospray ionisation-mass spectrometry analysis of astragaloside-IV in rat plasma. J Pharm Biomed Anal. 2006 Feb 24; 40(3):788-93.